UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
__________________________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Ticker symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
Item 8.01. Other Events.
Mutual Release of Claims
On November 8, 2023, ASP Isotopes Inc. (the “Company”) entered into a release agreement with Norsk Medisinsk Syklotronsenter AS (“NMS”), Radfarma AS (“Radfarma”), and certain board members and shareholders of Radfarma related to, among other things, claims asserted in a letter the Company received from a law firm acting on behalf of NMS, dated October 25, 2022 (the “NMS Letter”), which included a claim that the grant of the former license to the ASP technology to the Company by Klydon Proprietary Ltd violated a pre-existing exclusive sub-license to the ASP technology granted to Radfarma. In the release agreement, the parties agreed to a mutual release of claims related to, among other things, the facts, circumstances and matters asserted in the NMS Letter, including claims of a license of rights to the ASP technology. No party to the release agreement is required to make any payment or license any rights to any other party.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. |
| Description |
104 |
| Cover Page Interactive Date File (embedded within the Inline XBRL document) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ASP ISOTOPES INC |
| |
|
|
| |
Date: November 14, 2023 | By: | /s/ Paul Mann |
|
| Name: | Paul Mann |
|
| Title: | Chief Executive Officer |
|
3 |